TBL1XR1 and colorectal carcinoma: We also performed the survival analysis for cohort II patients, which demonstrated that high expression of TBL1XR1 can indicate high recurrence risk of stage I-III CRC patients (Fig. 3I, Table 5) from both univariate and multivariate analyses (HR = 3.716, 95% CI 1.858–7.433, P < 0.001).